Literature DB >> 11061883

Urinary level of nuclear matrix protein 22 in the diagnosis of bladder cancer: experience with 130 patients with biopsy confirmed tumor.

R Casella1, P Huber, A Blöchlinger, F Stoffel, P Dalquen, T C Gasser, K Lehmann.   

Abstract

PURPOSE: We prospectively evaluated the value of nuclear matrix protein 22 (NMP22dagger) and cytology in the diagnosis of bladder cancer.
MATERIALS AND METHODS: We analyzed NMP22 in voided urine from 235 patients before cystoscopy. Of the patients 130 had transitional cell carcinoma of the bladder and subsequently underwent surgery. In a subset of 200 patients bladder washout samples for cytology were collected during cystoscopy. The cutoff for NMP22 was 10.0 units per ml. For cytology only high grade atypia was considered positive.
RESULTS: Histology showed 77 superficial (pTa, pTis) and 53 invasive (pT1 or greater) tumors. Sensitivity of NMP22 was 51% and specificity was 83%. NMP22 sensitivity was 36% for superficial tumors and 73% for invasive transitional cell carcinoma. Overall sensitivity of cytology was 52% and specificity was 89%. Cytology sensitivity was 38% for superficial tumors and 83% for invasive transitional cell carcinoma. NMP22 sensitivity for grades 1, 2 and 3 tumors was 30%, 56% and 68%, respectively. Cytology sensitivity for grades 1, 2 and 3 tumors was 30%, 50% and 91%, respectively. Combined NMP22 and cytology had a sensitivity of 70%.
CONCLUSIONS: NMP22 has sensitivity and specificity similar to those of cytology from bladder washout samples. Particularly in low stage and low grade tumors both tests show the same disappointing sensitivity. Because of a false-negative rate of 49%, NMP22 cannot replace cystoscopy in clinical practice, as the danger of missing NMP22 negative tumors is too high to rely on its results in an individual patient.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11061883

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

1.  Comparison of the nuclear matrix protein 22 with voided urine cytology in the diagnosis of transitional cell carcinoma of the bladder.

Authors:  Murat Lekili; Ercüment Sener; Mehmet Akif Demir; Gökhan Temeltaş; Talha Müezzinoğlu; Coşkun Büyüksu
Journal:  Urol Res       Date:  2003-12-19

2.  Urinary tumor markers could predict survival in bladder carcinoma.

Authors:  Ragaa H M Salama; Tahia H Selem; Mohammed El-Gammal; Abd-Elmoneim A Elhagagy; Sally M Bakar
Journal:  Indian J Clin Biochem       Date:  2012-10-02

Review 3.  Urinary markers in screening patients with hematuria.

Authors:  Edmund Chiong; Kris E Gaston; H Barton Grossman
Journal:  World J Urol       Date:  2007-12-04       Impact factor: 4.226

4.  Comparison of the ImmunoCyt test and urinary cytology with other urine tests in the detection and surveillance of bladder cancer.

Authors:  Marieta I Toma; Martin G Friedrich; Stefan H Hautmann; K Thorsten Jäkel; Andreas Erbersdobler; Angelika Hellstern; Hartwig Huland
Journal:  World J Urol       Date:  2004-02-27       Impact factor: 4.226

Review 5.  Defining the role of NMP22 in bladder cancer surveillance.

Authors:  Carvell T Nguyen; J Stephen Jones
Journal:  World J Urol       Date:  2007-12-04       Impact factor: 4.226

6.  An ensemble approach of urine sediment image analysis and NMP22 test for detection of bladder cancer cells.

Authors:  Eun-Jung Cho; Chang Kwon Bang; Hyunjung Kim; Hae Kyung Lee
Journal:  J Clin Lab Anal       Date:  2020-07-10       Impact factor: 2.352

7.  A Systematic Review of the Diagnostic and Prognostic Value of Urinary Protein Biomarkers in Urothelial Bladder Cancer.

Authors:  Jamie J D'Costa; James C Goldsmith; Jayne S Wilson; Richard T Bryan; Douglas G Ward
Journal:  Bladder Cancer       Date:  2016-07-27

8.  The diagnostic and prognostic value of nuclear matrix protein 22 in bladder cancer.

Authors:  Xingxing Tang; Yudong Cao; Jia Liu; Shuo Wang; Yong Yang; Peng Du
Journal:  Transl Cancer Res       Date:  2020-11       Impact factor: 1.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.